In response to newly identified, community-based HIV epidemics, the AETC NCRC has pulled together the following AETC Program and U.S. Centers for Disease Control and Prevention resources for public he...
The HIV epidemic is an important public health priority. Transmissions continue to occur despite effective therapies that make HIV preventable and treatable. Approximately one-half of people with HIV...
To help HIV care providers engage patients in care and transmission prevention, the Centers for Disease Control and Prevention (CDC) developed a new and comprehensive Prevention IS Care resource kit f...
These presentation slides were from an annual event presented by the Pacific AETC's Arizona regional partner, California Prevention Training Center, and Curry International TB Center for Arizona-based...
Case-based training slides provide guidance for assessing atherosclerotic cardiovascular disease (ASCVD) risk in people with HIV.
The National HIV Curriculum (NHC) provides free, up-to-date content for clinicians to learn about HIV diagnosis, treatment, and prevention. The 37 lessons and corresponding question bank topics offer...
Each year HRSA's HIV/AIDS Bureau sponsors a conference for Ryan White Program clinicians to learn about advances in care and treatment. The AETC National Coordinating Resource Center and its partner,...
Immediate antiretroviral therapy (ART) means starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first clinic visit (and even on the same day as the HIV...
(Recorded 4/12/23)
This digital glossary of HIV-related terms includes both lay and scientific descriptions and illustrations. Materials are in the public domain and may be used freely. The glossary and images are also...
Training slides covering U.S. HHS treatment recommendations related to starting antiretroviral therapy (ART) in people with HIV infection. Topics include initial screening, regimen selection, and char...
After HIV diagnosis, timely entry into HIV medical care and retention in that care are essential to the provision of effective antiretroviral therapy (ART). ART adherence is among the key determinants...
Approximately 7/10 people with HIV in the U.S. are not virally suppressed. This infographic illustrates some of the barriers to achieving viral load suppression, and offers suggestions and resources t...
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and deat...
Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG) plus 2...
Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the DOR...
In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients. The approval specifies that DTG/3TC is intend...
